

# Invitation to AML-webinar with Alessandro Isidori



**Otsuka, in collaboration with CMYC\*,  
would like to invite hematologists to webinar  
Monday March 2, 2026 at 15.00-16.15**

The purpose is to increase the knowledge within AML and to discuss treatment options.

## **Agenda:**

- **Welcome and product information**, by Ivar Haukeland, BM, Otsuka Pharma Scandinavia AB
- **A short introduction to the landscape of less intensive treatment for elderly AML-patients**, by Prof, MD, PhD Bjørn Tore Gjertsen
- **Clinical management of elderly patients with AML not eligible for intensive chemotherapy: an overview**, by Alessandro Isidori, MD, PhD
- **Questions and discussion**, lead by Prof, MD, PhD Bjørn Tore Gjertsen

Please register latest February 27th by sending an email with the subject '**Isidori Webinar**' to [ivar.haukeland@otsuka.no](mailto:ivar.haukeland@otsuka.no). Provide your name and workplace, and you will receive an email with a link to the meeting and instructions for participation well in advance of the meeting.

Kind regards,

**Prof. MD, PhD Bjørn Tore Gjertsen**  
Director  
**The K.G. Jebsen-Centre for Myeloid  
Blood Cancer (CMYC\*)**

**Ivar Haukeland**  
Brand Manager Haematology,  
Nordics & Benelux  
**Otsuka Pharma Scandinavia AB**

\* Center for Myeloid Blood Cancer



**Alessandro Isidori, MD, PhD** is Hematologist at AORMN Hospital in Pesaro, Italy. His research activities are mainly focused on the diagnosis and treatment of acute myeloid leukemia.

He is member of the EHA Acute Myeloid Leukemia Scientific Working Group, EORTC Leukemia Group, of several international scientific societies (ASH, EHA, SIE) and International Ambassador for the Society of Hematologic Oncology (SOHO). He has published 145 papers in peer-reviewed journals and 5 book chapters.

Since 2010 he has been involved in many educational activities at national and international medical conferences, either as invited speaker or chairman or president.

He is Specialty Chief Editor for Frontiers in Oncology, Hematologic Malignancies Section, Associate Editor for Frontiers in Immunology, Cancer Immunity and Immunotherapy, and member of the Editorial Board and Reviewer for several highly cited international journals. He was the winner of the European Hematology Association (EHA) Clinical Research Grant in 2005.